ClinicalTrials.gg
Active, not recruitingNCT03003962Updated Jun 11, 2026Results posted

Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)

A Phase 3 interventional study of Durvalumab (MEDI4736) and Paclitaxel + carboplatin in Non Small Cell Lung Carcinoma NSCLC, sponsored by AstraZeneca. Active, not recruiting at 92 sites in 12 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-06-11.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
669
Allocation
Randomized
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung — 16 open to participants now, 37 under way, 11 of them phase 3. durvalumab · Carcinoma, Non-Small-Cell Lung.

Enrollment
9th of 94
669 · median 74
Started
2017
with 9 others
Phase 3
17 of 94
3 open now
Primary completion
2022-10
later than 4 of 36 live
Registered
22nd of 94
by date
Lead sponsor
25 of 94
AstraZeneca

Among the 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung, this one is the 9th largest by enrollment, is one of 10 that started in 2017, is one of 17 in phase 3, reaches primary completion later than 4 of the 36 other live ones, and was the 22nd registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

16 of the 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 16 open studies →

About durvalumab

durvalumab: first FDA approval 2017 (IMFINZI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This is a randomized, open-label, multi-center Phase III study to determine the efficacy and safety of durvalumab versus platinum-based SoC chemotherapy in the first-line treatment of advanced NSCLC in patients who are epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) wild-type and with PD-L1 high expression (PEARL)

Read the detailed description

Patients with stage IV NSCLC will be randomized in a 1:1 ratio to 2 treatment arms (durvalumab or SOC therapy). The dual primary objectives of this study are to assess the efficacy of durvalumab versus SoC in terms of OS (Overall Survival) in all randomized patients and in patients who are at low risk of EM (early mortality)

03

Conditions studied

  • Non Small Cell Lung Carcinoma NSCLC

Keywords

  • NSCLC
  • PD-L1
  • Durvalumab (MEDI4736)
  • OS
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged at least 18 years
  • Documented evidence of Stage IV NSCLC
  • No sensitizing EGFR mutation and ALK rearrangement
  • high expression
  • (ECOG) performance status of 0 or 1

Exclusion criteria

Exclusion Criteria:

  • Prior chemotherapy or any other systemic therapy for advanced NSCLC
  • Prior exposure to immune-mediated therapy, including, but not limited to, other anti-cytotoxic T-lymphocyte-associated antigen 4 (), anti-programmed cell death1 (PD-1), anti-programmed cell death ligand 1 (PD-L1), or anti PD-L2 antibodies, excluding therapeutic anticancer vaccines
  • or spinal cord compression unless the patient is stable and off for at least 14 days prior to start of study treatment
  • Mixed small-cell lung cancer and NSCLC histology, sarcomatoid variant
  • Active or prior documented or inflammatory disorders (e.g., colitis or Crohn's disease]
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
669 participants (actual)

Study arms

  • Experimental
    Arm 1: Durvalumab

    Anti-PD-L1 monoclonal Antibody monotherapy

    Drug: Durvalumab (MEDI4736)

  • Active comparator
    Arm 2: Standard of Care

    Standard of Care Platinum-Based chemotherapy

    Drug: Paclitaxel + carboplatin · Drug: Gemcitabine + cisplatin · Drug: Gemcitabine + carboplatin · Drug: Pemetrexed + cisplatin · Drug: Pemetrexed + carboplatin

Interventions

  • Anti-PD-L1 monoclonal Antibody monotherapy

  • DrugPaclitaxel + carboplatin

    Drug pages: Paclitaxel · Carboplatin

    Chemotherapy Agents

    Also known as: Platinum based Standard of Care Chemotherapy

  • DrugGemcitabine + cisplatin

    Drug pages: Gemcitabine · Cisplatin

    Chemotherapy Agents

    Also known as: Platinum based Standard of Care Chemotherapy

  • DrugGemcitabine + carboplatin

    Drug pages: Gemcitabine · Carboplatin

    Chemotherapy Agents

    Also known as: Platinum based Standard of Care Chemotherapy

  • DrugPemetrexed + cisplatin

    Drug pages: Pemetrexed · Cisplatin

    Chemotherapy Agent

    Also known as: Platinum based Standard of Care Chemotherapy

  • DrugPemetrexed + carboplatin

    Drug pages: Pemetrexed · Carboplatin

    Chemotherapy Agent

    Also known as: Platinum based Standard of Care Chemotherapy

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    OS is defined as the time from the date of randomization until death due to any cause (date of death or censoring-date of randomization + 1). Any participant not known to have died at the time of analysis was censored based on the last recorded date on which the participant was known to be alive.

    Time frame: From date of randomization until death due to any cause. Assessed up to a maximum of approximately 69 months [data cut-off (DCO) 27 October 2022]

  2. OS in Participants With LREM

    OS is defined as the time from the date of randomization until death due to any cause (date of death or censoring-date of randomization + 1). Any participant not known to have died at the time of analysis was censored based on the last recorded date on which the participant was known to be alive.

    Time frame: From date of randomization until death due to any cause. Assessed up to a maximum of approximately 69 months (DCO 27 October 2022)

Secondary outcomes

  1. OS in PD-L1 TC >= 50% Analysis Set

    OS is defined as the time from the date of randomization until death due to any cause (date of death or censoring-date of randomization + 1). Any participant not known to have died at the time of analysis was censored based on the last recorded date on which the participant was known to be alive.

    Time frame: From date of randomization until death due to any cause. Assessed up to a maximum of approximately 69 months (DCO 27 October 2022)

  2. OS in PD-L1 TC >= 50% LREM Analysis Set

    OS is defined as the time from the date of randomization until death due to ay cause (date of death or censoring-date of randomization + 1). Any participant not known to have died at the time of analysis was censored based on the last recorded date on which the participant was known to be alive.

    Time frame: From date of randomization until death due to any cause. Assessed up to a maximum of approximately 69 months (DCO 27 October 2022)

  3. Progression Free Survival (PFS) Based on Investigator Assessment According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)

    The PFS (per RECIST 1.1) was defined as the time from the date of randomization until the date of objective disease progression or death regardless of whether the participants withdrew from randomized therapy or received another anticancer therapy prior to progression (i.e., date of PFS event or censoring - date of randomization +1). Progression of disease per RECIST 1.1, when either 1 of the criteria met: Target lesion (TL): at least a 20% increase in the sum of diameters of TLs, for reference the smallest sum on study. In addition, the sum must also demonstrate an absolute increase of at least 5 millimeters (mm). Non-target lesion (NTL): Unequivocal progression of existing NTLs. It may be due to an important progression in 1 lesion only or in several lesions. In all cases the progression must be clinically significant for the physician to consider changing (or stopping) therapy. New lesions: the presence of 1 or more new lesions was assessed as progression.

    Time frame: Tumor assessments (per RECIST 1.1) every 6 weeks for the first 48 weeks relative to the date of randomization and then every 8 weeks thereafter until confirmed objective disease progression (up to a maximum of approximately 69 months DCO 27 October 2022)

  4. PFS Based on Investigator Assessment According to RECIST 1.1 in LREM Analysis Set

    The PFS (per RECIST 1.1 using Investigator assessments) was defined as the time from the date of randomization until the date of objective disease progression or death regardless of whether the participants withdrew from randomized therapy or received another anticancer therapy prior to progression (i.e., date of PFS event or censoring - date of randomization +1).

    Time frame: Tumor assessments (per RECIST 1.1) every 6 weeks for the first 48 weeks relative to the date of randomization and then every 8 weeks thereafter until confirmed objective disease progression (up to a maximum of approximately 69 months)

  5. PFS Based on Investigator Assessment According to RECIST 1.1 in PD-L1 TC >= 50% Analysis Set

    The PFS (per RECIST 1.1 using Investigator assessments) was defined as the time from the date of randomization until the date of objective disease progression or death regardless of whether the participants withdrew from randomized therapy or received another anticancer therapy prior to progression (i.e., date of PFS event or censoring - date of randomization +1).

    Time frame: Tumor assessments (per RECIST 1.1) every 6 weeks for the first 48 weeks relative to the date of randomization and then every 8 weeks thereafter until confirmed objective disease progression (up to a maximum of approximately 69 months)

  6. PFS Based on Investigator Assessment According to RECIST 1.1 in PD-L1 TC >= 50% LREM Analysis Set

    The PFS (per RECIST 1.1 using Investigator assessments) was defined as the time from the date of randomization until the date of objective disease progression or death regardless of whether the participants withdrew from randomized therapy or received another anticancer therapy prior to progression (i.e., date of PFS event or censoring - date of randomization +1).

    Time frame: Tumor assessments (per RECIST 1.1) every 6 weeks for the first 48 weeks relative to the date of randomization and then every 8 weeks thereafter until confirmed objective disease progression (up to a maximum of approximately 69 months)

  7. Objective Response Rate (ORR) as Per RECIST 1.1 Using Investigator Assessment

    ORR (per RECIST 1.1 using Investigator assessments) was defined as the percentage of participants with an unconfirmed response of complete response (CR) or partial response (PR). CR was defined as disappearance of all target lesions (TLs). Any pathological lymph nodes selected as TLs had a reduction in short axis to \< 10 millimeter (mm). PR was defined as at least a 30% decrease in the sum of diameters of TLs, with reference the baseline sum of diameters if criteria for PD are not met.

    Time frame: Tumor assessments (per RECIST 1.1) every 6 weeks for the first 48 weeks relative to the date of randomization and then every 8 weeks thereafter until confirmed objective disease progression (up to a maximum of approximately 69 months)

  8. ORR as Per RECIST 1.1 Using Investigator Assessment in PD-L1 TC >= 25% LREM Analysis Set

    ORR (per RECIST 1.1 using Investigator assessments)was defined as the percentage of participants with an unconfirmed response of CR or PR. CR was defined as disappearance of all TLs. Any pathological lymph nodes selected as TLs had a reduction in short axis to \< 10 mm. PR was defined as at least a 30% decrease in the sum of diameters of TLs, with reference the baseline sum of diameters if criteria for PD are not met.

    Time frame: Tumor assessments (per RECIST 1.1) every 6 weeks for the first 48 weeks relative to the date of randomization and then every 8 weeks thereafter until confirmed objective disease progression (up to a maximum of approximately 69 months)

  9. ORR as Per RECIST 1.1 Using Investigator Assessment in PD-L1 TC >= 50% Analysis Set

    ORR (per RECIST 1.1 using Investigator assessments) was defined as the percentage of participants with an unconfirmed response of CR or PR. CR was defined as disappearance of all TLs. Any pathological lymph nodes selected as TLs had a reduction in short axis to \< 10 mm. PR was defined as at least a 30% decrease in the sum of diameters of TLs, with reference the baseline sum of diameters if criteria for PD are not met.

    Time frame: Tumor assessments (per RECIST 1.1) every 6 weeks for the first 48 weeks relative to the date of randomization and then every 8 weeks thereafter until confirmed objective disease progression (up to a maximum of approximately 69 months)

  10. ORR as Per RECIST 1.1 Using Investigator Assessment in PD-L1 TC >= 50% LREM Analysis Set

    ORR (per RECIST 1.1 using Investigator assessments) was defined as the percentage of participants with an unconfirmed response of CR or PR. CR was defined as disappearance of all TLs. Any pathological lymph nodes selected as TLs had a reduction in short axis to \< 10 mm. PR was defined as at least a 30% decrease in the sum of diameters of TLs, with reference the baseline sum of diameters if criteria for PD are not met.

    Time frame: Tumor assessments (per RECIST 1.1) every 6 weeks for the first 48 weeks relative to the date of randomization and then every 8 weeks thereafter until confirmed objective disease progression (up to a maximum of approximately 69 months)

  11. Duration of Response (DoR) as Per RECIST 1.1 Using Investigator Assessment

    DoR (per RECIST 1.1 using Investigator assessments) was defined as the time from the date of first documented response until the first date of documented progression or death in the absence of disease progression (i.e. date of PFS event or censoring - date of first response + 1). DoR was calculated using the Kaplan-Meier technique.

    Time frame: Tumor assessments (per RECIST 1.1) every 6 weeks for the first 48 weeks relative to the date of randomization and then every 8 weeks thereafter until confirmed objective disease progression (up to a maximum of approximately 69 months)

  12. DoR as Per RECIST 1.1 Using Investigator Assessment in PD-L1 TC >=25% LREM Analysis Set

    DoR (per RECIST 1.1 using Investigator assessments) was defined as the time from the date of first documented response until the first date of documented progression or death in the absence of disease progression (i.e. date of PFS event or censoring - date of first response + 1). DoR was calculated using the Kaplan-Meier technique.

    Time frame: Tumor assessments (per RECIST 1.1) every 6 weeks for the first 48 weeks relative to the date of randomization and then every 8 weeks thereafter until confirmed objective disease progression (up to a maximum of approximately 69 months)

  13. DoR as Per RECIST 1.1 Using Investigator Assessment in PD-L1 TC >=50% Analysis Set

    DoR (per RECIST 1.1 using Investigator assessments) was defined as the time from the date of first documented response until the first date of documented progression or death in the absence of disease progression (i.e. date of PFS event or censoring - date of first response + 1). DoR was calculated using the Kaplan-Meier technique.

    Time frame: Tumor assessments (per RECIST 1.1) every 6 weeks for the first 48 weeks relative to the date of randomization and then every 8 weeks thereafter until confirmed objective disease progression (up to a maximum of approximately 69 months)

  14. DoR as Per RECIST 1.1 Using Investigator Assessment in PD-L1 TC >=50% LREM Analysis Set

    DoR (per RECIST 1.1 using Investigator assessments) was defined as the time from the date of first documented response until the first date of documented progression or death in the absence of disease progression (i.e. date of PFS event or censoring - date of first response + 1). DoR was calculated using the Kaplan-Meier technique.

    Time frame: Tumor assessments (per RECIST 1.1) every 6 weeks for the first 48 weeks relative to the date of randomization and then every 8 weeks thereafter until confirmed objective disease progression (up to a maximum of approximately 69 months)

  15. Alive and Progression-Free at 12 Months (APF12)

    The APF12 was defined as the Kaplan-Meier estimate of percentage of participants alive and progression free at 12 months based on PFS (per RECIST 1.1 as assessed using Investigator assessments) analysis.

    Time frame: From date of randomization until 12 months

  16. APF12 in PD-L1 TC >= 25% LREM Analysis Set

    The APF12 was defined as the Kaplan-Meier estimate of percentage of participants alive and progression free at 12 months based on PFS (per RECIST 1.1 as assessed using Investigator assessments) analysis.

    Time frame: From date of randomization until 12 months

  17. APF12 in PD-L1 TC >= 50% Analysis Set

    The APF12 was defined as the Kaplan-Meier estimate of percentage of participants alive and progression free at 12 months based on PFS (per RECIST 1.1 as assessed using Investigator assessments) analysis.

    Time frame: From date of randomization until 12 months

  18. APF12 in PD-L1 TC >= 50% LREM Analysis Set

    The APF12 was defined as the Kaplan-Meier estimate of percentage of participants alive and progression free at 12 months based on PFS (per RECIST 1.1 as assessed using Investigator assessments) analysis.

    Time frame: From date of randomization until 12 months

  19. Time From Randomization to Second Progression (PFS2)

    PFS2 was defined as the time from the date of randomization to the earliest of the progression events defined according to local clinical practice (subsequent to that used for the primary variable PFS) or death (i.e., date of PFS2 event or censoring - date of randomization + 1). PFS2 was calculated using the Kaplan-Meier technique.

    Time frame: Tumor assessments (per RECIST 1.1) until confirmed objective disease progression. Disease then assessed as per local practice until 2nd progression or death (up to a maximum of approximately 69 months)

  20. PFS2 in PD-L1 TC >= 25% LREM Analysis Set

    PFS2 was defined as the time from the date of randomization to the earliest of the progression events defined according to local clinical practice (subsequent to that used for the primary variable PFS) or death (i.e., date of PFS2 event or censoring - date of randomization + 1). PFS2 was calculated using the Kaplan-Meier technique.

    Time frame: Tumor assessments (per RECIST 1.1) until confirmed objective disease progression. Disease then assessed as per local practice until 2nd progression or death (up to a maximum of approximately 69 months)

  21. PFS2 in PD-L1 TC >= 50% Analysis Set

    PFS2 was defined as the time from the date of randomization to the earliest of the progression events defined according to local clinical practice (subsequent to that used for the primary variable PFS) or death (i.e., date of PFS2 event or censoring - date of randomization + 1). PFS2 was calculated using the Kaplan-Meier technique.

    Time frame: Tumor assessments (per RECIST 1.1) until confirmed objective disease progression. Disease then assessed as per local practice until 2nd progression or death (up to a maximum of approximately 69 months)

  22. PFS2 in PD-L1 TC >= 50% LREM Analysis Set

    PFS2 was defined as the time from the date of randomization to the earliest of the progression events defined according to local clinical practice (subsequent to that used for the primary variable PFS) or death (i.e., date of PFS2 event or censoring - date of randomization + 1). PFS2 was calculated using the Kaplan-Meier technique.

    Time frame: Tumor assessments (per RECIST 1.1) until confirmed objective disease progression. Disease then assessed as per local practice until 2nd progression or death (up to a maximum of approximately 69 months)

  23. OS at 18 Months

    OS was defined as the time from the date of randomization until death due to any cause. Any participant not known to have died at the time of analysis was censored based on the last recorded date on which the participant was known to be alive. The percentage of participants alive at 18 months were defined as the Kaplan-Meier estimate of OS at 18 months.

    Time frame: From date of randomization till 18 months.

  24. OS at 18 Months in PD-L1 TC > = 25% LREM Analysis Set

    OS was defined as the time from the date of randomization until death due to any cause. Any participant not known to have died at the time of analysis was censored based on the last recorded date on which the participant was known to be alive. The percentage of participants alive at 18 months were defined as the Kaplan-Meier estimate of OS at 18 months.

    Time frame: From date of randomization till 18 months

  25. OS at 18 Months in PD-L1 TC >= 50% Analysis Set

    OS was defined as the time from the date of randomization until death due to any cause. Any participant not known to have died at the time of analysis was censored based on the last recorded date on which the participant was known to be alive. The percentage of participants alive at 18 months were defined as the Kaplan-Meier estimate of OS at 18 months.

    Time frame: From date of randomization till 18 months

  26. OS at 18 Months in PD-L1 TC >= 50% LREM Analysis Set

    OS was defined as the time from the date of randomization until death due to any cause. Any participant not known to have died at the time of analysis was censored based on the last recorded date on which the participant was known to be alive. The percentage of participants alive at 18 months were defined as the Kaplan-Meier estimate of OS at 18 months.

    Time frame: From date of randomization till 18 months

  27. OS at 24 Months

    OS was defined as the time from the date of randomization until death due to any cause. Any participant not known to have died at the time of analysis was censored based on the last recorded date on which the participant was known to be alive. The percentage of participants alive at 24 months were defined as the Kaplan-Meier estimate of OS at 24 months.

    Time frame: From date of randomization till 24 months

  28. OS at 24 Months in PD-L1 TC > = 25% LREM Analysis Set

    OS was defined as the time from the date of randomization until death due to any cause. Any participant not known to have died at the time of analysis was censored based on the last recorded date on which the participant was known to be alive. The percentage of participants alive at 24 months were defined as the Kaplan-Meier estimate of OS at 24 months.

    Time frame: From date of randomization till 24 months

  29. OS at 24 Months in PD-L1 TC >= 50% Analysis Set

    OS was defined as the time from the date of randomization until death due to any cause. Any participant not known to have died at the time of analysis was censored based on the last recorded date on which the participant was known to be alive. The percentage of participants alive at 24 months were defined as the Kaplan-Meier estimate of OS at 24 months.

    Time frame: From date of randomization till 24 months

  30. OS at 24 Months in PD-L1 TC >= 50% LREM Analysis Set

    OS was defined as the time from the date of randomization until death due to any cause. Any participant not known to have died at the time of analysis was censored based on the last recorded date on which the participant was known to be alive. The percentage of participants alive at 24 months were defined as the Kaplan-Meier estimate of OS at 24 months.

    Time frame: From date of randomization till 24 months

  31. Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) 30-Item Core Quality of Life Questionnaire Version 3 (QLQ-C30)

    The EORTC QLQ-C30 consisted of 30 questions that were combined to produce 5 functional scales (physical, role, cognitive, emotional, and social), 3 symptom scales (fatigue, pain, and nausea/vomiting), 5 individual items (dyspnea, insomnia, appetite loss, constipation, and diarrhea), and a global measure of health status. The EORTC QLQ-C30 was scored according to the EORTC QLQ-C30 scoring manual. An outcome variable consisted of a score from 0 to 100. Higher scores on the global health status and functioning scales indicate better health status/function, but higher scores on symptom scales/items represent greater symptom severity. Baseline was defined as the last non-missing assessment prior to randomization. The mixed model repeated measures (MMRM) analysis of EORTC QLQ-C30 considered all data from baseline to PD or 12 months.

    Time frame: Baseline and 12 months

  32. Change From Baseline in EORTC QLQ-C30 in PD-L1 TC >= 25% LREM Analysis Set

    The EORTC QLQ-C30 consisted of 30 questions that were combined to produce 5 functional scales (physical, role, cognitive, emotional, and social), 3 symptom scales (fatigue, pain, and nausea/vomiting), 5 individual items (dyspnea, insomnia, appetite loss, constipation, and diarrhea), and a global measure of health status. The EORTC QLQ-C30 was scored according to the EORTC QLQ-C30 scoring manual. An outcome variable consisted of a score from 0 to 100. Higher scores on the global health status and functioning scales indicate better health status/function, but higher scores on symptom scales/items represent greater symptom severity. Baseline was defined as the last non-missing assessment prior to randomization. The MMRM analysis of EORTC QLQ-C30 considered all data from baseline to PD or 12 months.

    Time frame: Baseline and 12 months

  33. Time to Deterioration of EORTC QLQ-C30

    Time to symptom deterioration was defined as the time from the date of randomization until the date if the first clinically meaningful deterioration (a decrease in the function scales or the global health status/ health-related quality of life \[HRQoL\] from baseline of ≥10) that was confirmed at a subsequent visit or death in the absence of a clinically meaningful symptom deterioration, regardless of whether the participant withdraws from the study treatment or received another anticancer therapy prior to symptom deterioration. The EORTC QLQ-C30 consisted of 30 questions that were combined to produce 5 functional scales (physical, role, cognitive, emotional, and social), 3 symptom scales (fatigue, pain, and nausea/vomiting), 5 individual items (dyspnea, insomnia, appetite loss, constipation, and diarrhea), and a global measure of health status. The EORTC QLQ-C30 was scored according to the EORTC QLQ-C30 scoring manual.

    Time frame: From randomization until date of first symptom deterioration that is confirmed, assessed up to a maximum of approximately 69 months (DCO 27 October 2022)

  34. Time to Deterioration of EORTC QLQ-C30 in PD-L1 TC >= 25% LREM Analysis Set

    Time to symptom deterioration was defined as the time from the date of randomization until the date if the first clinically meaningful deterioration a decrease in the function scales or the global health status/ HRQoL from baseline of ≥10) that was confirmed at a subsequent visit or death (by any cause) in the absence of a clinically meaningful symptom deterioration, regardless of whether the participant withdraws from the study treatment or received another anticancer therapy prior to symptom deterioration. The EORTC QLQ-C30 consisted of 30 questions that were combined to produce 5 functional scales (physical, role, cognitive, emotional, and social), 3 symptom scales (fatigue, pain, and nausea/vomiting), 5 individual items (dyspnea, insomnia, appetite loss, constipation, and diarrhea), and a global measure of health status. The EORTC QLQ-C30 was scored according to the EORTC QLQ-C30 scoring manual.

    Time frame: From randomization until date of first symptom deterioration that is confirmed, assessed up to a maximum of approximately 69 months (DCO 27 October 2022)

  35. Change From Baseline in EORTC 13-Item Lung Cancer Quality of Life Questionnaire (QLQ-LC13)

    The QLQ-LC13 is a lung cancer specific module from the EORTC for lung cancer that comprised of 13 questions to assess lung cancer symptoms (cough, hemoptysis, dyspnea, and site-specific pain), treatment-related side-effects (sore mouth, dysphagia, peripheral neuropathy, and alopecia), and pain medication. An outcome variable consisted of a score from 0 to 100. Higher scores on symptom scales represent greater symptom severity. Baseline was defined as the last non-missing assessment prior to randomization. The MMRM analysis of EORTC QLQ-LC13 considered all data from baseline to PD or 12 months.

    Time frame: Baseline and 12 months

  36. Change From Baseline in EORTC QLQ-LC13 in PD-L1 TC >= 25% LREM Analysis Set

    The QLQ-LC13 is a lung cancer specific module from the EORTC for lung cancer that comprised of 13 questions to assess lung cancer symptoms (cough, hemoptysis, dyspnea, and site-specific pain), treatment-related side-effects (sore mouth, dysphagia, peripheral neuropathy, and alopecia), and pain medication. An outcome variable consisted of a score from 0 to 100. Higher scores on symptom scales represent greater symptom severity. Baseline was defined as the last non-missing assessment prior to randomization. The MMRM analysis of EORTC QLQ-LC13 considered all data from baseline to PD or 12 months.

    Time frame: Baseline and 12 months

  37. Time to Deterioration of EORTC QLQ-LC13

    Time to symptom deterioration was defined as the time from the date of randomization until the date if the first clinically meaningful symptom deterioration a decrease in the function scales or the global health status/ HRQoL from baseline of ≥10) that was confirmed at a subsequent visit or death (by any cause) in the absence of a clinically meaningful symptom deterioration, regardless of whether the participant withdraws from the study treatment or received another anticancer therapy prior to symptom deterioration. The QLQ-LC13 is a lung cancer specific module from the EORTC for lung cancer that comprised of 13 questions to assess lung cancer symptoms (cough, hemoptysis, dyspnea, and site-specific pain), treatment-related side-effects (sore mouth, dysphagia, peripheral neuropathy, and alopecia), and pain medication.

    Time frame: From randomization until date of first symptom deterioration that is confirmed, assessed up to maximum of approximately 69 months (DCO 27 October 2022)

  38. Time to Deterioration of EORTC QLQ-LC13 in PD-L1 TC >= 25% LREM Analysis Set

    Time to symptom deterioration was defined as the time from the date of randomization until the date if the first clinically meaningful symptom deterioration a decrease in the function scales or the global health status/ HRQoL from baseline of ≥10) that was confirmed at a subsequent visit or death (by any cause) in the absence of a clinically meaningful symptom deterioration, regardless of whether the participant withdraws from the study treatment or received another anticancer therapy prior to symptom deterioration. The QLQ-LC13 is a lung cancer specific module from the EORTC for lung cancer that comprised of 13 questions to assess lung cancer symptoms (cough, hemoptysis, dyspnea, and site-specific pain), treatment-related side-effects (sore mouth, dysphagia, peripheral neuropathy, and alopecia), and pain medication.

    Time frame: From randomization until date of first symptom deterioration that is confirmed, assessed up to maximum of approximately 69 months (DCO 27 October 2022)

  39. Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status

    ECOG performance status was assessed at the times specified based on the following and scored as 0: fully active: able to carry out all usual activities without restrictions. 1: Restricted in strenuous activity, but ambulatory and able to carry out any work activities; up and about more than 50% of waking hours. 3: Capable of only limited self-care; confined to bed or chair more than 50% of waking hours. 4: Completely disabled; unable to carry out any self-care and totally confined to bed or chair and 5: death. Data for only participants with restricted activity has been reported.

    Time frame: From Baseline and until follow-up period of 57 months

  40. Number of Participants With ECOG Performance Status in PD-L1 TC >=25% LREM Analysis Set

    ECOG performance status was assessed at the times specified based on the following and scored as 0: fully active: able to carry out all usual activities without restrictions. 1: Restricted in strenuous activity, but ambulatory and able to carry out any work activities; up and about more than 50% of waking hours. 3: Capable of only limited self-care; confined to bed or chair more than 50% of waking hours. 4: Completely disabled; unable to carry out any self-care and totally confined to bed or chair and 5: death. Data for only participants with restricted activity has been reported.

    Time frame: From Baseline and until follow-up period of 57 months

  41. Percentage of Participants With Antidrug Antibody (ADA) Response to Durvalumab

    Treatment-emergent ADA positive was defined as either treatment-induced or treatment-boosted ADA. Treatment-boosted ADA was defined as a baseline positive ADA titer that was boosted to a 4-fold or higher-level following study drug administration. Persistently positive was defined as positive at least 2 post-baseline assessments with at least 16 weeks between the first and last positive assessment or positive at last post-baseline assessment. Transiently positive was defined as having at least 1 post-baseline ADA positive assessment and not fulfilling the conditions of persistently positive.

    Time frame: Up to 24 weeks

  42. Percentage of Participants With ADA Response to Durvalumab in LREM Analysis Set

    Treatment-emergent ADA positive was defined as either treatment-induced or treatment-boosted ADA. Treatment-boosted ADA was defined as a baseline positive ADA titer that was boosted to a 4-fold or higher-level following study drug administration. Persistently positive was defined as positive at least 2 post-baseline assessments with at least 16 weeks between the first and last positive assessment or positive at last post-baseline assessment. Transiently positive was defined as having at least 1 post-baseline ADA positive assessment and not fulfilling the conditions of persistently positive.

    Time frame: Up to 24 weeks

07

Results

Posted Dec 26, 2023

Participant flow

This Phase III, open-label, multi-center study was conducted in participants with programmed cell death ligand 1 (PD-L1)- tumor cell (TC) \>= 25% advanced non small-cell lung cancer (NSCLC) at 85 centers in 10 countries (China, Russia, Hungary, Poland, South Korea, Vietnam, Turkey, Australia, Taiwan, and Thailand). First participant was enrolled on 02 January 2017 and last participant was enrolled on 25 January 2019.

Participant flow — Overall Study
MilestoneDurvalumabPlatinum-based SoC
Started335334
Pd l1 tc ≥ 25% lrem analysis set278271
Pd l1 tc ≥ 50% analysis set247246
Pd l1 tc ≥ 50% lrem analysis set207199
Completed10
Not completed334334
Withdrew: Withdrawal by subject517
Withdrew: Death274277
Withdrew: Participants ongoing at dco5540

Outcome measures

PrimaryOverall Survival (OS)

OS is defined as the time from the date of randomization until death due to any cause (date of death or censoring-date of randomization + 1). Any participant not known to have died at the time of analysis was censored based on the last recorded date on which the participant was known to be alive.

Time frame:
From date of randomization until death due to any cause. Assessed up to a maximum of approximately 69 months [data cut-off (DCO) 27 October 2022]
Reported as:
Median · months
Overall Survival (OS)
monthsDurvalumabPlatinum-based SoC
Overall Survival (OS)14.6 (12.2 to 16.9)12.8 (10.1 to 14.7)
Statistical analysis
  • Durvalumab vs Platinum-based SoC · Stratified Log-rank test · p = 0.037 · Hazard ratio (hr): 0.84 · 95% CI 0.706 to 0.989The HR and confidence interval (CI) were calculated using a stratified Cox proportional hazards model
PrimaryOS in Participants With LREM

OS is defined as the time from the date of randomization until death due to any cause (date of death or censoring-date of randomization + 1). Any participant not known to have died at the time of analysis was censored based on the last recorded date on which the participant was known to be alive.

Time frame:
From date of randomization until death due to any cause. Assessed up to a maximum of approximately 69 months (DCO 27 October 2022)
Reported as:
Median · months
OS in Participants With LREM
monthsDurvalumabPlatinum-based SoC
OS in Participants With LREM14.6 (12.6 to 17.2)15.0 (13.1 to 16.8)
Statistical analysis
  • Durvalumab vs Platinum-based SoC · Stratified log-rank test · p = 0.628 · Hazard ratio (hr): 0.96 · 95% CI 0.793 to 1.151The HR and CI were calculated using a stratified Cox proportional hazards model.
SecondaryOS in PD-L1 TC >= 50% Analysis Set

OS is defined as the time from the date of randomization until death due to any cause (date of death or censoring-date of randomization + 1). Any participant not known to have died at the time of analysis was censored based on the last recorded date on which the participant was known to be alive.

Time frame:
From date of randomization until death due to any cause. Assessed up to a maximum of approximately 69 months (DCO 27 October 2022)
Reported as:
Median · months
OS in PD-L1 TC >= 50% Analysis Set
monthsDurvalumabPlatinum-based SoC
OS in PD-L1 TC >= 50% Analysis Set14.6 (12.0 to 17.7)11.8 (9.8 to 14.7)
SecondaryOS in PD-L1 TC >= 50% LREM Analysis Set

OS is defined as the time from the date of randomization until death due to ay cause (date of death or censoring-date of randomization + 1). Any participant not known to have died at the time of analysis was censored based on the last recorded date on which the participant was known to be alive.

Time frame:
From date of randomization until death due to any cause. Assessed up to a maximum of approximately 69 months (DCO 27 October 2022)
Reported as:
Median · months
OS in PD-L1 TC >= 50% LREM Analysis Set
monthsDurvalumabPlatinum-based SoC
OS in PD-L1 TC >= 50% LREM Analysis Set14.9 (12.6 to 19.0)14.9 (11.8 to 17.7)
SecondaryProgression Free Survival (PFS) Based on Investigator Assessment According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)

The PFS (per RECIST 1.1) was defined as the time from the date of randomization until the date of objective disease progression or death regardless of whether the participants withdrew from randomized therapy or received another anticancer therapy prior to progression (i.e., date of PFS event or censoring - date of randomization +1). Progression of disease per RECIST 1.1, when either 1 of the criteria met: Target lesion (TL): at least a 20% increase in the sum of diameters of TLs, for reference the smallest sum on study. In addition, the sum must also demonstrate an absolute increase of at least 5 millimeters (mm). Non-target lesion (NTL): Unequivocal progression of existing NTLs. It may be due to an important progression in 1 lesion only or in several lesions. In all cases the progression must be clinically significant for the physician to consider changing (or stopping) therapy. New lesions: the presence of 1 or more new lesions was assessed as progression.

Time frame:
Tumor assessments (per RECIST 1.1) every 6 weeks for the first 48 weeks relative to the date of randomization and then every 8 weeks thereafter until confirmed objective disease progression (up to a maximum of approximately 69 months DCO 27 October 2022)
Reported as:
Median · months
Progression Free Survival (PFS) Based on Investigator Assessment According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)
monthsDurvalumabPlatinum-based SoC
Progression Free Survival (PFS) Based on Investigator Assessment According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)5.4 (4.2 to 5.7)4.8 (4.3 to 5.6)
SecondaryPFS Based on Investigator Assessment According to RECIST 1.1 in LREM Analysis Set

The PFS (per RECIST 1.1 using Investigator assessments) was defined as the time from the date of randomization until the date of objective disease progression or death regardless of whether the participants withdrew from randomized therapy or received another anticancer therapy prior to progression (i.e., date of PFS event or censoring - date of randomization +1).

Time frame:
Tumor assessments (per RECIST 1.1) every 6 weeks for the first 48 weeks relative to the date of randomization and then every 8 weeks thereafter until confirmed objective disease progression (up to a maximum of approximately 69 months)
Reported as:
Median · months
PFS Based on Investigator Assessment According to RECIST 1.1 in LREM Analysis Set
monthsDurvalumabPlatinum-based SoC
PFS Based on Investigator Assessment According to RECIST 1.1 in LREM Analysis Set5.5 (4.4 to 6.4)5.6 (4.8 to 5.9)
SecondaryPFS Based on Investigator Assessment According to RECIST 1.1 in PD-L1 TC >= 50% Analysis Set

The PFS (per RECIST 1.1 using Investigator assessments) was defined as the time from the date of randomization until the date of objective disease progression or death regardless of whether the participants withdrew from randomized therapy or received another anticancer therapy prior to progression (i.e., date of PFS event or censoring - date of randomization +1).

Time frame:
Tumor assessments (per RECIST 1.1) every 6 weeks for the first 48 weeks relative to the date of randomization and then every 8 weeks thereafter until confirmed objective disease progression (up to a maximum of approximately 69 months)
Reported as:
Median · months
PFS Based on Investigator Assessment According to RECIST 1.1 in PD-L1 TC >= 50% Analysis Set
monthsDurvalumabPlatinum-based SoC
PFS Based on Investigator Assessment According to RECIST 1.1 in PD-L1 TC >= 50% Analysis Set5.6 (4.7 to 6.5)4.5 (4.2 to 5.6)
SecondaryPFS Based on Investigator Assessment According to RECIST 1.1 in PD-L1 TC >= 50% LREM Analysis Set

The PFS (per RECIST 1.1 using Investigator assessments) was defined as the time from the date of randomization until the date of objective disease progression or death regardless of whether the participants withdrew from randomized therapy or received another anticancer therapy prior to progression (i.e., date of PFS event or censoring - date of randomization +1).

Time frame:
Tumor assessments (per RECIST 1.1) every 6 weeks for the first 48 weeks relative to the date of randomization and then every 8 weeks thereafter until confirmed objective disease progression (up to a maximum of approximately 69 months)
Reported as:
Median · months
PFS Based on Investigator Assessment According to RECIST 1.1 in PD-L1 TC >= 50% LREM Analysis Set
monthsDurvalumabPlatinum-based SoC
PFS Based on Investigator Assessment According to RECIST 1.1 in PD-L1 TC >= 50% LREM Analysis Set5.7 (5.3 to 7.0)5.5 (4.2 to 5.7)
SecondaryObjective Response Rate (ORR) as Per RECIST 1.1 Using Investigator Assessment

ORR (per RECIST 1.1 using Investigator assessments) was defined as the percentage of participants with an unconfirmed response of complete response (CR) or partial response (PR). CR was defined as disappearance of all target lesions (TLs). Any pathological lymph nodes selected as TLs had a reduction in short axis to \< 10 millimeter (mm). PR was defined as at least a 30% decrease in the sum of diameters of TLs, with reference the baseline sum of diameters if criteria for PD are not met.

Time frame:
Tumor assessments (per RECIST 1.1) every 6 weeks for the first 48 weeks relative to the date of randomization and then every 8 weeks thereafter until confirmed objective disease progression (up to a maximum of approximately 69 months)
Reported as:
Number · percentage of participants
Objective Response Rate (ORR) as Per RECIST 1.1 Using Investigator Assessment
percentage of participantsDurvalumabPlatinum-based SoC
Objective Response Rate (ORR) as Per RECIST 1.1 Using Investigator Assessment37.6 (0.324 to 0.430)37.4 (0.322 to 0.429)
SecondaryORR as Per RECIST 1.1 Using Investigator Assessment in PD-L1 TC >= 25% LREM Analysis Set

ORR (per RECIST 1.1 using Investigator assessments)was defined as the percentage of participants with an unconfirmed response of CR or PR. CR was defined as disappearance of all TLs. Any pathological lymph nodes selected as TLs had a reduction in short axis to \< 10 mm. PR was defined as at least a 30% decrease in the sum of diameters of TLs, with reference the baseline sum of diameters if criteria for PD are not met.

Time frame:
Tumor assessments (per RECIST 1.1) every 6 weeks for the first 48 weeks relative to the date of randomization and then every 8 weeks thereafter until confirmed objective disease progression (up to a maximum of approximately 69 months)
Reported as:
Number · percentage of participants
ORR as Per RECIST 1.1 Using Investigator Assessment in PD-L1 TC >= 25% LREM Analysis Set
percentage of participantsDurvalumabPlatinum-based SoC
ORR as Per RECIST 1.1 Using Investigator Assessment in PD-L1 TC >= 25% LREM Analysis Set38.5 (0.327 to 0.445)40.2 (0.343 to 0.463)
SecondaryORR as Per RECIST 1.1 Using Investigator Assessment in PD-L1 TC >= 50% Analysis Set

ORR (per RECIST 1.1 using Investigator assessments) was defined as the percentage of participants with an unconfirmed response of CR or PR. CR was defined as disappearance of all TLs. Any pathological lymph nodes selected as TLs had a reduction in short axis to \< 10 mm. PR was defined as at least a 30% decrease in the sum of diameters of TLs, with reference the baseline sum of diameters if criteria for PD are not met.

Time frame:
Tumor assessments (per RECIST 1.1) every 6 weeks for the first 48 weeks relative to the date of randomization and then every 8 weeks thereafter until confirmed objective disease progression (up to a maximum of approximately 69 months)
Reported as:
Number · percentage of participants
ORR as Per RECIST 1.1 Using Investigator Assessment in PD-L1 TC >= 50% Analysis Set
percentage of participantsDurvalumabPlatinum-based SoC
ORR as Per RECIST 1.1 Using Investigator Assessment in PD-L1 TC >= 50% Analysis Set42.1 (0.359 to 0.485)40.7 (0.345 to 0.471)
SecondaryORR as Per RECIST 1.1 Using Investigator Assessment in PD-L1 TC >= 50% LREM Analysis Set

ORR (per RECIST 1.1 using Investigator assessments) was defined as the percentage of participants with an unconfirmed response of CR or PR. CR was defined as disappearance of all TLs. Any pathological lymph nodes selected as TLs had a reduction in short axis to \< 10 mm. PR was defined as at least a 30% decrease in the sum of diameters of TLs, with reference the baseline sum of diameters if criteria for PD are not met.

Time frame:
Tumor assessments (per RECIST 1.1) every 6 weeks for the first 48 weeks relative to the date of randomization and then every 8 weeks thereafter until confirmed objective disease progression (up to a maximum of approximately 69 months)
Reported as:
Number · percentage of participants
ORR as Per RECIST 1.1 Using Investigator Assessment in PD-L1 TC >= 50% LREM Analysis Set
percentage of participantsDurvalumabPlatinum-based SoC
ORR as Per RECIST 1.1 Using Investigator Assessment in PD-L1 TC >= 50% LREM Analysis Set44.0 (0.371 to 0.510)43.7 (0.367 to 0.509)
SecondaryDuration of Response (DoR) as Per RECIST 1.1 Using Investigator Assessment

DoR (per RECIST 1.1 using Investigator assessments) was defined as the time from the date of first documented response until the first date of documented progression or death in the absence of disease progression (i.e. date of PFS event or censoring - date of first response + 1). DoR was calculated using the Kaplan-Meier technique.

Time frame:
Tumor assessments (per RECIST 1.1) every 6 weeks for the first 48 weeks relative to the date of randomization and then every 8 weeks thereafter until confirmed objective disease progression (up to a maximum of approximately 69 months)
Reported as:
Median · months
Duration of Response (DoR) as Per RECIST 1.1 Using Investigator Assessment
monthsDurvalumabPlatinum-based SoC
Duration of Response (DoR) as Per RECIST 1.1 Using Investigator Assessment11.9 (9.7 to 18.7)4.2 (3.3 to 4.6)
SecondaryDoR as Per RECIST 1.1 Using Investigator Assessment in PD-L1 TC >=25% LREM Analysis Set

DoR (per RECIST 1.1 using Investigator assessments) was defined as the time from the date of first documented response until the first date of documented progression or death in the absence of disease progression (i.e. date of PFS event or censoring - date of first response + 1). DoR was calculated using the Kaplan-Meier technique.

Time frame:
Tumor assessments (per RECIST 1.1) every 6 weeks for the first 48 weeks relative to the date of randomization and then every 8 weeks thereafter until confirmed objective disease progression (up to a maximum of approximately 69 months)
Reported as:
Median · months
DoR as Per RECIST 1.1 Using Investigator Assessment in PD-L1 TC >=25% LREM Analysis Set
monthsDurvalumabPlatinum-based SoC
DoR as Per RECIST 1.1 Using Investigator Assessment in PD-L1 TC >=25% LREM Analysis Set11.6 (8.2 to 15.7)4.2 (4.0 to 5.4)
SecondaryDoR as Per RECIST 1.1 Using Investigator Assessment in PD-L1 TC >=50% Analysis Set

DoR (per RECIST 1.1 using Investigator assessments) was defined as the time from the date of first documented response until the first date of documented progression or death in the absence of disease progression (i.e. date of PFS event or censoring - date of first response + 1). DoR was calculated using the Kaplan-Meier technique.

Time frame:
Tumor assessments (per RECIST 1.1) every 6 weeks for the first 48 weeks relative to the date of randomization and then every 8 weeks thereafter until confirmed objective disease progression (up to a maximum of approximately 69 months)
Reported as:
Median · months
DoR as Per RECIST 1.1 Using Investigator Assessment in PD-L1 TC >=50% Analysis Set
monthsDurvalumabPlatinum-based SoC
DoR as Per RECIST 1.1 Using Investigator Assessment in PD-L1 TC >=50% Analysis Set12.2 (8.3 to 21.2)4.2 (3.0 to 4.6)
SecondaryDoR as Per RECIST 1.1 Using Investigator Assessment in PD-L1 TC >=50% LREM Analysis Set

DoR (per RECIST 1.1 using Investigator assessments) was defined as the time from the date of first documented response until the first date of documented progression or death in the absence of disease progression (i.e. date of PFS event or censoring - date of first response + 1). DoR was calculated using the Kaplan-Meier technique.

Time frame:
Tumor assessments (per RECIST 1.1) every 6 weeks for the first 48 weeks relative to the date of randomization and then every 8 weeks thereafter until confirmed objective disease progression (up to a maximum of approximately 69 months)
Reported as:
Median · months
DoR as Per RECIST 1.1 Using Investigator Assessment in PD-L1 TC >=50% LREM Analysis Set
monthsDurvalumabPlatinum-based SoC
DoR as Per RECIST 1.1 Using Investigator Assessment in PD-L1 TC >=50% LREM Analysis Set12.2 (8.2 to 19.7)4.2 (3.9 to 5.4)
SecondaryAlive and Progression-Free at 12 Months (APF12)

The APF12 was defined as the Kaplan-Meier estimate of percentage of participants alive and progression free at 12 months based on PFS (per RECIST 1.1 as assessed using Investigator assessments) analysis.

Time frame:
From date of randomization until 12 months
Reported as:
Number · percentage of participants
Alive and Progression-Free at 12 Months (APF12)
percentage of participantsDurvalumabPlatinum-based SoC
Alive and Progression-Free at 12 Months (APF12)25.5 (20.8 to 30.4)13.3 (9.6 to 17.5)
SecondaryAPF12 in PD-L1 TC >= 25% LREM Analysis Set

The APF12 was defined as the Kaplan-Meier estimate of percentage of participants alive and progression free at 12 months based on PFS (per RECIST 1.1 as assessed using Investigator assessments) analysis.

Time frame:
From date of randomization until 12 months
Reported as:
Number · percentage of participants
APF12 in PD-L1 TC >= 25% LREM Analysis Set
percentage of participantsDurvalumabPlatinum-based SoC
APF12 in PD-L1 TC >= 25% LREM Analysis Set24.1 (19.1 to 29.5)16.4 (11.9 to 21.5)
SecondaryAPF12 in PD-L1 TC >= 50% Analysis Set

The APF12 was defined as the Kaplan-Meier estimate of percentage of participants alive and progression free at 12 months based on PFS (per RECIST 1.1 as assessed using Investigator assessments) analysis.

Time frame:
From date of randomization until 12 months
Reported as:
Number · percentage of participants
APF12 in PD-L1 TC >= 50% Analysis Set
percentage of participantsDurvalumabPlatinum-based SoC
APF12 in PD-L1 TC >= 50% Analysis Set26.1 (20.7 to 31.9)11.7 (7.7 to 16.5)
SecondaryAPF12 in PD-L1 TC >= 50% LREM Analysis Set

The APF12 was defined as the Kaplan-Meier estimate of percentage of participants alive and progression free at 12 months based on PFS (per RECIST 1.1 as assessed using Investigator assessments) analysis.

Time frame:
From date of randomization until 12 months
Reported as:
Number · percentage of participants
APF12 in PD-L1 TC >= 50% LREM Analysis Set
percentage of participantsDurvalumabPlatinum-based SoC
APF12 in PD-L1 TC >= 50% LREM Analysis Set26.5 (20.5 to 32.8)14.5 (9.6 to 20.4)
SecondaryTime From Randomization to Second Progression (PFS2)

PFS2 was defined as the time from the date of randomization to the earliest of the progression events defined according to local clinical practice (subsequent to that used for the primary variable PFS) or death (i.e., date of PFS2 event or censoring - date of randomization + 1). PFS2 was calculated using the Kaplan-Meier technique.

Time frame:
Tumor assessments (per RECIST 1.1) until confirmed objective disease progression. Disease then assessed as per local practice until 2nd progression or death (up to a maximum of approximately 69 months)
Reported as:
Median · months
Time From Randomization to Second Progression (PFS2)
monthsDurvalumabPlatinum-based SoC
Time From Randomization to Second Progression (PFS2)11.3 (9.8 to 12.7)9.3 (8.1 to 10.7)
SecondaryPFS2 in PD-L1 TC >= 25% LREM Analysis Set

PFS2 was defined as the time from the date of randomization to the earliest of the progression events defined according to local clinical practice (subsequent to that used for the primary variable PFS) or death (i.e., date of PFS2 event or censoring - date of randomization + 1). PFS2 was calculated using the Kaplan-Meier technique.

Time frame:
Tumor assessments (per RECIST 1.1) until confirmed objective disease progression. Disease then assessed as per local practice until 2nd progression or death (up to a maximum of approximately 69 months)
Reported as:
Median · months
PFS2 in PD-L1 TC >= 25% LREM Analysis Set
monthsDurvalumabPlatinum-based SoC
PFS2 in PD-L1 TC >= 25% LREM Analysis Set11.8 (10.1 to 12.9)10.9 (9.3 to 13.1)
SecondaryPFS2 in PD-L1 TC >= 50% Analysis Set

PFS2 was defined as the time from the date of randomization to the earliest of the progression events defined according to local clinical practice (subsequent to that used for the primary variable PFS) or death (i.e., date of PFS2 event or censoring - date of randomization + 1). PFS2 was calculated using the Kaplan-Meier technique.

Time frame:
Tumor assessments (per RECIST 1.1) until confirmed objective disease progression. Disease then assessed as per local practice until 2nd progression or death (up to a maximum of approximately 69 months)
Reported as:
Median · months
PFS2 in PD-L1 TC >= 50% Analysis Set
monthsDurvalumabPlatinum-based SoC
PFS2 in PD-L1 TC >= 50% Analysis Set11.3 (9.7 to 12.9)8.8 (8.0 to 10.9)
SecondaryPFS2 in PD-L1 TC >= 50% LREM Analysis Set

PFS2 was defined as the time from the date of randomization to the earliest of the progression events defined according to local clinical practice (subsequent to that used for the primary variable PFS) or death (i.e., date of PFS2 event or censoring - date of randomization + 1). PFS2 was calculated using the Kaplan-Meier technique.

Time frame:
Tumor assessments (per RECIST 1.1) until confirmed objective disease progression. Disease then assessed as per local practice until 2nd progression or death (up to a maximum of approximately 69 months)
Reported as:
Median · months
PFS2 in PD-L1 TC >= 50% LREM Analysis Set
monthsDurvalumabPlatinum-based SoC
PFS2 in PD-L1 TC >= 50% LREM Analysis Set12.0 (10.1 to 13.8)10.9 (8.8 to 13.1)
SecondaryOS at 18 Months

OS was defined as the time from the date of randomization until death due to any cause. Any participant not known to have died at the time of analysis was censored based on the last recorded date on which the participant was known to be alive. The percentage of participants alive at 18 months were defined as the Kaplan-Meier estimate of OS at 18 months.

Time frame:
From date of randomization till 18 months.
Reported as:
Number · percentage of participants
OS at 18 Months
percentage of participantsDurvalumabPlatinum-based SoC
OS at 18 Months42.5 (37.1 to 47.7)34.2 (29.0 to 39.4)
SecondaryOS at 18 Months in PD-L1 TC > = 25% LREM Analysis Set

OS was defined as the time from the date of randomization until death due to any cause. Any participant not known to have died at the time of analysis was censored based on the last recorded date on which the participant was known to be alive. The percentage of participants alive at 18 months were defined as the Kaplan-Meier estimate of OS at 18 months.

Time frame:
From date of randomization till 18 months
Reported as:
Number · percentage of participants
OS at 18 Months in PD-L1 TC > = 25% LREM Analysis Set
percentage of participantsDurvalumabPlatinum-based SoC
OS at 18 Months in PD-L1 TC > = 25% LREM Analysis Set43.0 (37.1 to 48.8)41.4 (35.4 to 47.4)
SecondaryOS at 18 Months in PD-L1 TC >= 50% Analysis Set

OS was defined as the time from the date of randomization until death due to any cause. Any participant not known to have died at the time of analysis was censored based on the last recorded date on which the participant was known to be alive. The percentage of participants alive at 18 months were defined as the Kaplan-Meier estimate of OS at 18 months.

Time frame:
From date of randomization till 18 months
Reported as:
Number · percentage of participants
OS at 18 Months in PD-L1 TC >= 50% Analysis Set
percentage of participantsDurvalumabPlatinum-based SoC
OS at 18 Months in PD-L1 TC >= 50% Analysis Set43.2 (36.9 to 49.3)34.9 (28.8 to 41.0)
SecondaryOS at 18 Months in PD-L1 TC >= 50% LREM Analysis Set

OS was defined as the time from the date of randomization until death due to any cause. Any participant not known to have died at the time of analysis was censored based on the last recorded date on which the participant was known to be alive. The percentage of participants alive at 18 months were defined as the Kaplan-Meier estimate of OS at 18 months.

Time frame:
From date of randomization till 18 months
Reported as:
Number · percentage of participants
OS at 18 Months in PD-L1 TC >= 50% LREM Analysis Set
percentage of participantsDurvalumabPlatinum-based SoC
OS at 18 Months in PD-L1 TC >= 50% LREM Analysis Set44.3 (37.4 to 51.0)42.2 (35.2 to 49.1)
SecondaryOS at 24 Months

OS was defined as the time from the date of randomization until death due to any cause. Any participant not known to have died at the time of analysis was censored based on the last recorded date on which the participant was known to be alive. The percentage of participants alive at 24 months were defined as the Kaplan-Meier estimate of OS at 24 months.

Time frame:
From date of randomization till 24 months
Reported as:
Number · percentage of participants
OS at 24 Months
percentage of participantsDurvalumabPlatinum-based SoC
OS at 24 Months34.6 (29.5 to 39.7)27.2 (22.4 to 32.1)
SecondaryOS at 24 Months in PD-L1 TC > = 25% LREM Analysis Set

OS was defined as the time from the date of randomization until death due to any cause. Any participant not known to have died at the time of analysis was censored based on the last recorded date on which the participant was known to be alive. The percentage of participants alive at 24 months were defined as the Kaplan-Meier estimate of OS at 24 months.

Time frame:
From date of randomization till 24 months
Reported as:
Number · percentage of participants
OS at 24 Months in PD-L1 TC > = 25% LREM Analysis Set
percentage of participantsDurvalumabPlatinum-based SoC
OS at 24 Months in PD-L1 TC > = 25% LREM Analysis Set34.7 (29.1 to 40.3)32.8 (27.2 to 38.6)
SecondaryOS at 24 Months in PD-L1 TC >= 50% Analysis Set

OS was defined as the time from the date of randomization until death due to any cause. Any participant not known to have died at the time of analysis was censored based on the last recorded date on which the participant was known to be alive. The percentage of participants alive at 24 months were defined as the Kaplan-Meier estimate of OS at 24 months.

Time frame:
From date of randomization till 24 months
Reported as:
Number · percentage of participants
OS at 24 Months in PD-L1 TC >= 50% Analysis Set
percentage of participantsDurvalumabPlatinum-based SoC
OS at 24 Months in PD-L1 TC >= 50% Analysis Set37.0 (31.0 to 43.1)27.0 (21.5 to 32.8)
SecondaryOS at 24 Months in PD-L1 TC >= 50% LREM Analysis Set

OS was defined as the time from the date of randomization until death due to any cause. Any participant not known to have died at the time of analysis was censored based on the last recorded date on which the participant was known to be alive. The percentage of participants alive at 24 months were defined as the Kaplan-Meier estimate of OS at 24 months.

Time frame:
From date of randomization till 24 months
Reported as:
Number · percentage of participants
OS at 24 Months in PD-L1 TC >= 50% LREM Analysis Set
percentage of participantsDurvalumabPlatinum-based SoC
OS at 24 Months in PD-L1 TC >= 50% LREM Analysis Set36.9 (30.3 to 43.5)32.6 (26.1 to 39.3)
SecondaryChange From Baseline in European Organization for Research and Treatment of Cancer (EORTC) 30-Item Core Quality of Life Questionnaire Version 3 (QLQ-C30)

The EORTC QLQ-C30 consisted of 30 questions that were combined to produce 5 functional scales (physical, role, cognitive, emotional, and social), 3 symptom scales (fatigue, pain, and nausea/vomiting), 5 individual items (dyspnea, insomnia, appetite loss, constipation, and diarrhea), and a global measure of health status. The EORTC QLQ-C30 was scored according to the EORTC QLQ-C30 scoring manual. An outcome variable consisted of a score from 0 to 100. Higher scores on the global health status and functioning scales indicate better health status/function, but higher scores on symptom scales/items represent greater symptom severity. Baseline was defined as the last non-missing assessment prior to randomization. The mixed model repeated measures (MMRM) analysis of EORTC QLQ-C30 considered all data from baseline to PD or 12 months.

Time frame:
Baseline and 12 months
Reported as:
Mean · scores on a scale
Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) 30-Item Core Quality of Life Questionnaire Version 3 (QLQ-C30)
scores on a scaleDurvalumabPlatinum-based SoC
Global health status-0.7 ± 1.19-7.4 ± 1.27
Physical functioning-3.3 ± 1.23-6.1 ± 1.30
Fatigue1.4 ± 1.337.2 ± 1.43
Appetite loss-1.1 ± 1.399.1 ± 1.50
SecondaryChange From Baseline in EORTC QLQ-C30 in PD-L1 TC >= 25% LREM Analysis Set

The EORTC QLQ-C30 consisted of 30 questions that were combined to produce 5 functional scales (physical, role, cognitive, emotional, and social), 3 symptom scales (fatigue, pain, and nausea/vomiting), 5 individual items (dyspnea, insomnia, appetite loss, constipation, and diarrhea), and a global measure of health status. The EORTC QLQ-C30 was scored according to the EORTC QLQ-C30 scoring manual. An outcome variable consisted of a score from 0 to 100. Higher scores on the global health status and functioning scales indicate better health status/function, but higher scores on symptom scales/items represent greater symptom severity. Baseline was defined as the last non-missing assessment prior to randomization. The MMRM analysis of EORTC QLQ-C30 considered all data from baseline to PD or 12 months.

Time frame:
Baseline and 12 months
Reported as:
Mean · scores on a scale
Change From Baseline in EORTC QLQ-C30 in PD-L1 TC >= 25% LREM Analysis Set
scores on a scaleDurvalumabPlatinum-based SoC
Global health status-1.4 ± 1.23-7.3 ± 1.31
Physical functioning-3.9 ± 1.22-6.0 ± 1.29
Fatigue2.2 ± 1.337.7 ± 1.42
Appetite loss-0.2 ± 1.439.8 ± 1.52
SecondaryTime to Deterioration of EORTC QLQ-C30

Time to symptom deterioration was defined as the time from the date of randomization until the date if the first clinically meaningful deterioration (a decrease in the function scales or the global health status/ health-related quality of life \[HRQoL\] from baseline of ≥10) that was confirmed at a subsequent visit or death in the absence of a clinically meaningful symptom deterioration, regardless of whether the participant withdraws from the study treatment or received another anticancer therapy prior to symptom deterioration. The EORTC QLQ-C30 consisted of 30 questions that were combined to produce 5 functional scales (physical, role, cognitive, emotional, and social), 3 symptom scales (fatigue, pain, and nausea/vomiting), 5 individual items (dyspnea, insomnia, appetite loss, constipation, and diarrhea), and a global measure of health status. The EORTC QLQ-C30 was scored according to the EORTC QLQ-C30 scoring manual.

Time frame:
From randomization until date of first symptom deterioration that is confirmed, assessed up to a maximum of approximately 69 months (DCO 27 October 2022)
Reported as:
Median · months
Time to Deterioration of EORTC QLQ-C30
monthsDurvalumabPlatinum-based SoC
Global health status7.3 (5.5 to 9.1)3.8 (3.6 to 5.5)
Physical functioning7.4 (5.6 to 9.8)3.8 (3.6 to 5.2)
Appetite loss9.2 (7.3 to 11.4)3.6 (2.3 to 3.8)
Fatigue4.9 (3.7 to 7.0)1.8 (1.6 to 2.6)
SecondaryTime to Deterioration of EORTC QLQ-C30 in PD-L1 TC >= 25% LREM Analysis Set

Time to symptom deterioration was defined as the time from the date of randomization until the date if the first clinically meaningful deterioration a decrease in the function scales or the global health status/ HRQoL from baseline of ≥10) that was confirmed at a subsequent visit or death (by any cause) in the absence of a clinically meaningful symptom deterioration, regardless of whether the participant withdraws from the study treatment or received another anticancer therapy prior to symptom deterioration. The EORTC QLQ-C30 consisted of 30 questions that were combined to produce 5 functional scales (physical, role, cognitive, emotional, and social), 3 symptom scales (fatigue, pain, and nausea/vomiting), 5 individual items (dyspnea, insomnia, appetite loss, constipation, and diarrhea), and a global measure of health status. The EORTC QLQ-C30 was scored according to the EORTC QLQ-C30 scoring manual.

Time frame:
From randomization until date of first symptom deterioration that is confirmed, assessed up to a maximum of approximately 69 months (DCO 27 October 2022)
Reported as:
Median · months
Time to Deterioration of EORTC QLQ-C30 in PD-L1 TC >= 25% LREM Analysis Set
monthsDurvalumabPlatinum-based SoC
Global health status7.4 (5.6 to 9.2)5.5 (3.7 to 6.5)
Physical functioning7.4 (5.6 to 10.1)4.7 (3.7 to 5.8)
Appetite loss9.3 (7.3 to 11.6)3.7 (2.6 to 5.0)
Fatigue5.5 (3.8 to 7.4)1.8 (1.6 to 3.3)
SecondaryChange From Baseline in EORTC 13-Item Lung Cancer Quality of Life Questionnaire (QLQ-LC13)

The QLQ-LC13 is a lung cancer specific module from the EORTC for lung cancer that comprised of 13 questions to assess lung cancer symptoms (cough, hemoptysis, dyspnea, and site-specific pain), treatment-related side-effects (sore mouth, dysphagia, peripheral neuropathy, and alopecia), and pain medication. An outcome variable consisted of a score from 0 to 100. Higher scores on symptom scales represent greater symptom severity. Baseline was defined as the last non-missing assessment prior to randomization. The MMRM analysis of EORTC QLQ-LC13 considered all data from baseline to PD or 12 months.

Time frame:
Baseline and 12 months
Reported as:
Mean · scores on a scale
Change From Baseline in EORTC 13-Item Lung Cancer Quality of Life Questionnaire (QLQ-LC13)
scores on a scaleDurvalumabPlatinum-based SoC
Cough-6.4 ± 1.30-7.9 ± 1.41
Dyspnea2.4 ± 1.244.1 ± 1.32
Chest pain-1.0 ± 1.26-0.2 ± 1.37
SecondaryChange From Baseline in EORTC QLQ-LC13 in PD-L1 TC >= 25% LREM Analysis Set

The QLQ-LC13 is a lung cancer specific module from the EORTC for lung cancer that comprised of 13 questions to assess lung cancer symptoms (cough, hemoptysis, dyspnea, and site-specific pain), treatment-related side-effects (sore mouth, dysphagia, peripheral neuropathy, and alopecia), and pain medication. An outcome variable consisted of a score from 0 to 100. Higher scores on symptom scales represent greater symptom severity. Baseline was defined as the last non-missing assessment prior to randomization. The MMRM analysis of EORTC QLQ-LC13 considered all data from baseline to PD or 12 months.

Time frame:
Baseline and 12 months
Reported as:
Mean · scores on a scale
Change From Baseline in EORTC QLQ-LC13 in PD-L1 TC >= 25% LREM Analysis Set
scores on a scaleDurvalumabPlatinum-based SoC
Cough-6.6 ± 1.38-8.6 ± 1.48
Dyspnea2.9 ± 1.283.9 ± 1.35
Chest pain-0.7 ± 1.30-1.0 ± 1.40
SecondaryTime to Deterioration of EORTC QLQ-LC13

Time to symptom deterioration was defined as the time from the date of randomization until the date if the first clinically meaningful symptom deterioration a decrease in the function scales or the global health status/ HRQoL from baseline of ≥10) that was confirmed at a subsequent visit or death (by any cause) in the absence of a clinically meaningful symptom deterioration, regardless of whether the participant withdraws from the study treatment or received another anticancer therapy prior to symptom deterioration. The QLQ-LC13 is a lung cancer specific module from the EORTC for lung cancer that comprised of 13 questions to assess lung cancer symptoms (cough, hemoptysis, dyspnea, and site-specific pain), treatment-related side-effects (sore mouth, dysphagia, peripheral neuropathy, and alopecia), and pain medication.

Time frame:
From randomization until date of first symptom deterioration that is confirmed, assessed up to maximum of approximately 69 months (DCO 27 October 2022)
Reported as:
Median · months
Time to Deterioration of EORTC QLQ-LC13
monthsDurvalumabPlatinum-based SoC
Cough7.5 (6.4 to 10.1)6.6 (5.6 to 8.2)
Dyspnea2.8 (1.9 to 4.6)3.6 (2.4 to 3.8)
Chest pain9.0 (6.3 to 11.9)6.4 (4.6 to 7.2)
SecondaryTime to Deterioration of EORTC QLQ-LC13 in PD-L1 TC >= 25% LREM Analysis Set

Time to symptom deterioration was defined as the time from the date of randomization until the date if the first clinically meaningful symptom deterioration a decrease in the function scales or the global health status/ HRQoL from baseline of ≥10) that was confirmed at a subsequent visit or death (by any cause) in the absence of a clinically meaningful symptom deterioration, regardless of whether the participant withdraws from the study treatment or received another anticancer therapy prior to symptom deterioration. The QLQ-LC13 is a lung cancer specific module from the EORTC for lung cancer that comprised of 13 questions to assess lung cancer symptoms (cough, hemoptysis, dyspnea, and site-specific pain), treatment-related side-effects (sore mouth, dysphagia, peripheral neuropathy, and alopecia), and pain medication.

Time frame:
From randomization until date of first symptom deterioration that is confirmed, assessed up to maximum of approximately 69 months (DCO 27 October 2022)
Reported as:
Median · months
Time to Deterioration of EORTC QLQ-LC13 in PD-L1 TC >= 25% LREM Analysis Set
monthsDurvalumabPlatinum-based SoC
Cough9.2 (6.4 to 12.3)8.2 (6.4 to 11.1)
Dyspnea3.6 (2.0 to 4.7)3.6 (2.4 to 3.8)
Chest pain9.8 (6.4 to 12.6)6.6 (5.8 to 9.2)
SecondaryNumber of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status

ECOG performance status was assessed at the times specified based on the following and scored as 0: fully active: able to carry out all usual activities without restrictions. 1: Restricted in strenuous activity, but ambulatory and able to carry out any work activities; up and about more than 50% of waking hours. 3: Capable of only limited self-care; confined to bed or chair more than 50% of waking hours. 4: Completely disabled; unable to carry out any self-care and totally confined to bed or chair and 5: death. Data for only participants with restricted activity has been reported.

Time frame:
From Baseline and until follow-up period of 57 months
Reported as:
Number · number of participants
Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status
number of participantsDurvalumabPlatinum-based SoC
Restricted activity, Baseline267255
Restricted activity, Follow-up Month 5702
SecondaryNumber of Participants With ECOG Performance Status in PD-L1 TC >=25% LREM Analysis Set

ECOG performance status was assessed at the times specified based on the following and scored as 0: fully active: able to carry out all usual activities without restrictions. 1: Restricted in strenuous activity, but ambulatory and able to carry out any work activities; up and about more than 50% of waking hours. 3: Capable of only limited self-care; confined to bed or chair more than 50% of waking hours. 4: Completely disabled; unable to carry out any self-care and totally confined to bed or chair and 5: death. Data for only participants with restricted activity has been reported.

Time frame:
From Baseline and until follow-up period of 57 months
Reported as:
Number · number of participants
Number of Participants With ECOG Performance Status in PD-L1 TC >=25% LREM Analysis Set
number of participantsDurvalumabPlatinum-based SoC
Restricted activity, Baseline221203
Restricted activity, Follow-up Month 5702
SecondaryPercentage of Participants With Antidrug Antibody (ADA) Response to Durvalumab

Treatment-emergent ADA positive was defined as either treatment-induced or treatment-boosted ADA. Treatment-boosted ADA was defined as a baseline positive ADA titer that was boosted to a 4-fold or higher-level following study drug administration. Persistently positive was defined as positive at least 2 post-baseline assessments with at least 16 weeks between the first and last positive assessment or positive at last post-baseline assessment. Transiently positive was defined as having at least 1 post-baseline ADA positive assessment and not fulfilling the conditions of persistently positive.

Time frame:
Up to 24 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With Antidrug Antibody (ADA) Response to Durvalumab
percentage of participantsDurvalumab
Treatment-emergent ADA positive0.8
Treatment-boosted ADA0.4
Persistently positive0
Transiently positive0.8
SecondaryPercentage of Participants With ADA Response to Durvalumab in LREM Analysis Set

Treatment-emergent ADA positive was defined as either treatment-induced or treatment-boosted ADA. Treatment-boosted ADA was defined as a baseline positive ADA titer that was boosted to a 4-fold or higher-level following study drug administration. Persistently positive was defined as positive at least 2 post-baseline assessments with at least 16 weeks between the first and last positive assessment or positive at last post-baseline assessment. Transiently positive was defined as having at least 1 post-baseline ADA positive assessment and not fulfilling the conditions of persistently positive.

Time frame:
Up to 24 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With ADA Response to Durvalumab in LREM Analysis Set
percentage of participantsDurvalumab
Treatment-emergent ADA positive1.0
Treatment-boosted ADA0.5
Persistently positive0
Transiently positive1.0

Adverse events

Collected over From first administration of study treatment up to 90 days after the last dose of durvalumab or 30 days after last dose of platinum based SoC or date of initiation of the first subsequent therapy, whichever occurs first, for approximately 69 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Durvalumab274/335 (81.8%)132/335 (39.4%)271/335 (80.9%)
Platinum-based SoC277/334 (82.9%)104/327 (31.8%)294/327 (89.9%)
Most frequent serious events
Showing 10 of 165
Most frequent serious events
EventDurvalumabPlatinum-based SoC
PneumoniaInfections and infestations26/33517/327
AnaemiaBlood and lymphatic system disorders5/33519/327
MyelosuppressionBlood and lymphatic system disorders1/33514/327
Platelet count decreasedInvestigations0/3358/327
DeathGeneral disorders7/3351/327
Pleural effusionRespiratory, thoracic and mediastinal disorders6/3351/327
DyspnoeaRespiratory, thoracic and mediastinal disorders5/3354/327
HaemoptysisRespiratory, thoracic and mediastinal disorders5/3354/327
PneumonitisRespiratory, thoracic and mediastinal disorders5/3350/327
Pulmonary embolismRespiratory, thoracic and mediastinal disorders5/3351/327
Most frequent other events
Showing 10 of 42
Most frequent other events
EventDurvalumabPlatinum-based SoC
AnaemiaBlood and lymphatic system disorders81/335168/327
NauseaGastrointestinal disorders28/335107/327
Decreased appetiteMetabolism and nutrition disorders66/33594/327
Neutrophil count decreasedInvestigations9/33585/327
White blood cell count decreasedInvestigations13/33584/327
VomitingGastrointestinal disorders17/33559/327
ConstipationGastrointestinal disorders32/33557/327
Platelet count decreasedInvestigations15/33556/327
NeutropeniaBlood and lymphatic system disorders4/33554/327
LeukopeniaBlood and lymphatic system disorders1/33551/327

Baseline characteristics

The Full analysis set (FAS) included all randomized participants.

Age, Continuous
Age, Continuous(years)DurvalumabPlatinum-based SoCTotal
Mean60.7 ± 9.7361.9 ± 8.7161.3 ± 9.25
Sex: Female, Male
Sex: Female, Male(Participants)DurvalumabPlatinum-based SoCTotal
Female6765132
Male268269537
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)DurvalumabPlatinum-based SoCTotal
White7361134
Asian262273535
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)DurvalumabPlatinum-based SoCTotal
Hispanic or Latino268
Not Hispanic or Latino333328661
08

Study locations

92 sites
  • Research Site
    Anaheim, California 92801, United States
  • Research Site
    Box Hill, 3128, Australia
  • Research Site
    Gosford, 2250, Australia
  • Research Site
    Kogarah, 2217, Australia
  • Research Site
    St Leonards, 2065, Australia
  • Research Site
    Beijing, 100032, China
  • Research Site
    Beijing, 100142, China
  • Research Site
    Beijing, 100853, China
  • Research Site
    Bengbu, 233004, China
  • Research Site
    Changchun, 130000, China
  • Research Site
    Changsha, 410013, China
  • Research Site
    Chengdu, 610041, China
  • Research Site
    Chongqing, 400030, China
  • Research Site
    Guangzhou, 510080, China
  • Research Site
    Guangzhou, 510095, China
  • Research Site
    Haikou, 570311, China
  • Research Site
    Hangzhou, 310003, China
  • Research Site
    Hangzhou, 310006, China
  • Research Site
    Hangzhou, 310009, China
  • Research Site
    Hangzhou, 310022, China
  • Research Site
    Jinan, 250031, China
  • Research Site
    Linhai, 317000, China
  • Research Site
    Nanchang, 330006, China
  • Research Site
    Nanjing, 210009, China
  • Research Site
    Ningbo, 315010, China
  • Research Site
    Shanghai, 200030, China
  • Research Site
    Shenyang, 110042, China
  • Research Site
    Shijiazhuang, 050020, China
  • Research Site
    Ürümqi, 830000, China
  • Research Site
    Ürümqi, 830054, China
  • Research Site
    Wanzhou, 404000, China
  • Research Site
    Wenzhou, CN-325000, China
  • Research Site
    Wuhan, 430010, China
  • Research Site
    Wuhan, 430022, China
  • Research Site
    Wuhan, 430030, China
  • Research Site
    Xi'an, 710038, China
  • Research Site
    Xi'an, 710061, China
  • Research Site
    Zhengzhou, 450008, China
  • Research Site
    Zhuhai, 519099, China
  • Research Site
    Budapest, 1083, Hungary
  • Research Site
    Budapest, 1121, Hungary
  • Research Site
    Budapest, 1122, Hungary
  • Research Site
    Deszk, 6772, Hungary
  • Research Site
    Farkasgyepü, 8582, Hungary
  • Research Site
    Gyöngyös - Mátraháza, 3200, Hungary
  • Research Site
    Székesfehérvár, 8000, Hungary
  • Research Site
    Törökbálint, 2045, Hungary
  • Research Site
    Almelo, 7600SZ, Netherlands
  • Research Site
    Bialystok, 15-027, Poland
  • Research Site
    Grudziądz, 86-300, Poland
  • Research Site
    Koszalin, 75-581, Poland
  • Research Site
    Lublin, 20-090, Poland
  • Research Site
    Mrozy, 05-320, Poland
  • Research Site
    Warsaw, 02-781, Poland
  • Research Site
    Wroclaw, 53-413, Poland
  • Research Site
    Arkhangelsk, 163045, Russia
  • Research Site
    Moscow, 115478, Russia
  • Research Site
    Novosibirsk, 630108, Russia
  • Research Site
    Omsk, 644013, Russia
  • Research Site
    Rostov-on-Don, 344037, Russia
  • Research Site
    Saint Petersburg, 194291, Russia
  • Research Site
    Saint Petersburg, 196603, Russia
  • Research Site
    Saint Petersburg, 197183, Russia
  • Research Site
    Saint Petersburg, 197342, Russia
  • Research Site
    Saint Petersburg, 197758, Russia
  • Research Site
    Volgograd, 400138, Russia
  • Research Site
    Changwon-si, 51353, South Korea
  • Research Site
    Cheongju-si, 28644, South Korea
  • Research Site
    Daegu, 42415, South Korea
  • Research Site
    Incheon, 21565, South Korea
  • Research Site
    Jinju, 660-702, South Korea
  • Research Site
    Seoul, 03722, South Korea
  • Research Site
    Suwon, 16499, South Korea
  • Research Site
    Taichung, 402, Taiwan
  • Research Site
    Taichung, 40705, Taiwan
  • Research Site
    Taipei, 112, Taiwan
  • Research Site
    Taipei, 235, Taiwan
  • Research Site
    Bangkok, 10330, Thailand
  • Research Site
    Bangkok, 10700, Thailand
  • Research Site
    Muang, 50200, Thailand
  • Research Site
    Songkhla, 90110, Thailand
  • Research Site
    Ankara, 06490, Turkey (Türkiye)
  • Research Site
    Istanbul, 34030, Turkey (Türkiye)
  • Research Site
    Istanbul, 34854, Turkey (Türkiye)
  • Research Site
    Malatya, 44100, Turkey (Türkiye)
  • Research Site
    Pamukkale, 20070, Turkey (Türkiye)
  • Research Site
    Can Tho, 900000, Vietnam
  • Research Site
    Hanoi, 100000, Vietnam
  • Research Site
    Hanoi, 10000, Vietnam
  • Research Site
    Ho Chi Minh City, 10000, Vietnam
  • Research Site
    Ho Chi Minh City, 700000, Vietnam
  • Research Site
    Ho Chi Minh City, 70000, Vietnam
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2017 to primary completion in Oct 2022, 69 months.

Results were first posted in Dec 2023, 1 year 1 month after primary completion.

Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's 69 months is above that.

Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2016
First posted
Dec 28, 2016
StartActual
Jan 2, 2017
Primary completionActual
Oct 27, 2022
CompletionEst.
Jun 30, 2026
Results first posted
Dec 26, 2023
Last update
Jun 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03003962
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Dec 28, 2016
Start date
Jan 2, 2017
Primary completion
Oct 27, 2022
Completion
Jun 30, 2026 (estimated)
Results posted
Dec 26, 2023
Last update
Jun 11, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Durvalumab

Start the discussion